2 new studies indicate that immunotherapy drugs, namely Keytruda (pembrolizumab), Opdivo (nivolumab), and Yervoy (ipilimumab) may increase survival rates for patients with lung cancer. Results showed that Keytruda togetehr with chemotherapy lessened a patients change of dying within 11 months by more than 50% compared to chemotherapy treatment alone, while Opdivo and Yervoy saw a 42% less likely death rate. According to the authors of the studies, the findings "offer an encouraging note in an effort to improve the odds against what is the leading cause of cancer-related death."
To read more about this study, click here.
No comments:
Post a Comment